THERAPY DOSSIER · th-259e4e8d77bb

3% NaCl adenosine, lidocaine and magnesium (ALM) bolus followed by 0.9% NaCl ALM stabilisation drip

Procedure

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Haemorrhage/shock
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 28520687 ↗2017Reported benefit

3% NaCl adenosine, lidocaine, Mg2+ (ALM) bolus and 4 hours drip infusion reduces noncompressible hemorrhage by 60% in a rat model.

RatHaemorrhage/shockUncontrolledSprague-DawleyMalen = n = 16 per group across five groupsIntravenousBolus 0.7 mL/kg of 3% NaCl with or without ALM; drip 0.5 mL…Bolus 15 minutes after liver resection; drip commenced at 60 minutes

Model: Noncompressible hepatic haemorrhage and shock induced by liver resection in ventilated, instrumented rats with single or double laparotomy

ALM therapy gave 0% mortality (25% with double laparotomy) versus 87.5% with no treatment and 37.5% with saline, raised cardiac output 2.4-fold and reduced bleeding by up to 60% compared with saline and 75% compared with Hextend; Hextend increased mortality and bleeding.

Extraction: extract · Subtype source: llm · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.

Loading the evidence…